SKL 10406Alternative Names: SKL DEP; SKL-10406
Latest Information Update: 11 Apr 2016
At a glance
- Originator SK Holdings
- Developer SK biopharmaceuticals
- Class Antidepressants
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 03 Jul 2007 SK Bio-Pharmaceuticals is now called SK Drug Development Center